(NASDAQ: STRO) Sutro Biopharma's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 11.12%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 32.52%.
Sutro Biopharma's earnings in 2026 is -$180,636,000.On average, 16 Wall Street analysts forecast STRO's earnings for 2026 to be -$145,207,947, with the lowest STRO earnings forecast at -$167,759,998, and the highest STRO earnings forecast at -$111,077,265. On average, 16 Wall Street analysts forecast STRO's earnings for 2027 to be -$114,930,729, with the lowest STRO earnings forecast at -$168,947,209, and the highest STRO earnings forecast at -$59,717,087.
In 2028, STRO is forecast to generate -$116,714,863 in earnings, with the lowest earnings forecast at -$162,982,962 and the highest earnings forecast at -$43,525,574.